TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,137.11−0.09%Brent$109.08−0.12%BTC$81,810.54−0.25%ETH$2,403.34−0.17%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,137.11−0.09%Brent$109.08−0.12%BTC$81,810.54−0.25%ETH$2,403.34−0.17%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Acumen Pharmaceuticals Inc · Overview · TradingHolo

Markets › United States › NAS › ABOS

A

Acumen Pharmaceuticals Inc

NAS:ABOSHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$1.77+4.73%At closeAt close · Tue 20 Oct · ≈ AED 6.50 · Market cap $128M · Next earnings Wed 11 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

+4.7%

1M

−34.2%

3M

−23.5%

6M

−40.1%

1Y

−25.9%

Why it's moving today

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

GlobeNewswire · Tue 20 Oct

✦ This week in three lines

No written digest yet for ABOS. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR —

Valuation

P/E vs sector−1.0× vs −1.7×

Price / Book vs sector1.7× vs 2.0×

Price / Sales vs sector—

Price / Free cash flow vs sector−1.1× vs −1.6×

Forecasts

6 buy0 hold0 sell6 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 84 beats

Dividends

Yield0.0%

Annual payout—

Payout ratio0.0%

Next ex-date—

Years of growth—

Latest news

All ABOS news →

GLAcumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

GlobeNewswire · 4 h ago

GLAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

globenewswire · 39 d ago

GLAcumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 69 d ago

Key facts

At close · Tue 20 Oct

Market cap (USD)$128M

P/E−1.0×

Dividend yield0.0%

52-week range$1.50 – $3.60

Avg volume (20d)607,479

Shares outstanding72,317,300

Beta0.33

Short interest5.0% of float

Next earningsWed 11 Nov

Radar Score

—

Value—

Quality—

Momentum—

Income—

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular…

Sector

Healthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

—−1.33%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

—−0.69%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

—−0.96%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

—+1.36%